Compare RCG & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RCG | MDCX |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 16.6M |
| IPO Year | 1996 | N/A |
| Metric | RCG | MDCX |
|---|---|---|
| Price | $2.85 | $0.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 4.4K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.40 | $0.25 |
| 52 Week High | $3.31 | $3.69 |
| Indicator | RCG | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 50.35 | 51.30 |
| Support Level | $2.47 | $0.27 |
| Resistance Level | $2.82 | $0.36 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 36.84 | 41.53 |
RENN Fund Inc is a registered, non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with above-market rates of return through capital appreciation and income by a long-term, value oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities, including convertible and non-convertible debt securities or loans, distressed debt, warrants, preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. To a lesser extent, the fund sells short stocks, exchange-traded funds, and exchange-traded notes. It invests in various industries, including communication services, surgical and medical instruments, oil and gas, etc.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.